v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flow from operating activities:    
Net Income (Loss) $ 2,822,068 $ 1,265,553
Adjustment to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 1,254,973 1,245,362
Stock options expense 330,374 205,457
Restricted common stock expense 598,142 1,518,104
Accreted interest expense 1,040,293 0
Adjustment to contingent earnout liability 0 1,748,526
Changes in operating assets and liabilities:    
Accounts receivable 228,194 (341,434)
Prepaid expenses and other current assets (109,291) 63,296
Prepaid royalties (410,372) 1,066,312
Accounts payable and accrued expenses (1,262,918) (1,426,282)
Deferred revenue 782,957 1,678,272
Net cash provided by operating activities 5,274,420 7,023,166
Cash flow from investing activities:    
Purchase of property and equipment (39,771) (19,261)
Net cash used in investing activities (39,771) (19,261)
Cash flow from financing activities:    
Proceeds from the exercise of stock options 157,500 180,800
Common stock repurchase (53,039) (934,577)
Payment of contingent acquisition consideration - Scite and FIZ (4,950,209) (124,107)
Net cash used in financing activities (4,845,748) (877,884)
Effect of exchange rate changes 14,070 1,260
Net increase in cash and cash equivalents 402,971 6,127,281
Cash and cash equivalents, beginning of period 12,227,312 6,100,031
Cash and cash equivalents, end of period 12,630,283 12,227,312
Supplemental disclosures of cash flow information:    
Cash paid for income taxes 71,213 82,811
Non-cash investing and financing activities:    
Contingent consideration accrual on asset acquisition   $ 31,359
Common stock issued for Scite earnout payment $ 2,906,856